Spanish National Research Council (CSIC)

New gene editing technologies, such as gene drive tools, open the door to deliberately extinguishing species. An analysis article published in Science examines the ethical implications of this possibility based on three specific examples: the eradication of rats, the cattle barren worm, and the Anopheles gambiae mosquito, which transmits malaria. The analysis attempts to answer the question: ‘When and under what circumstances could the intentional eradication of a species be justified?".

A team from the Children's Hospital of Philadelphia and Penn Medicine (United States) has successfully treated a baby diagnosed with a rare genetic disorder using personalised CRISPR gene editing therapy. The baby, known only by the initials KJ, was born with a rare metabolic disease known as severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. After spending the first months of his life in hospital on a very restrictive diet, KJ received the first dose of his tailored therapy in February 2025, between six and seven months of age. The treatment, which is being used for the first time for this type of disorder, was administered safely, and the baby is now growing well and improving. The case is detailed in a study published by The New England Journal of Medicine (NEJM).

A team from the Centre for Genomic Regulation (CRG) and Pompeu Fabra University (UPF) in Barcelona has developed an artificial intelligence tool capable of designing regulatory sequences for genes that do not exist in nature. When introduced into cells, these enhancers can increase or decrease gene activity in a specific way depending on the type of cell targeted. According to the authors, ‘the potential applications are enormous. It's like writing software, but for biology.’ The results are published in the journal Cell.

Using data from the James Webb Space Telescope (JWST), a group of astronomers has detected the chemical fingerprints of dimethyl sulfide (DMS) and dimethyl disulfide (DMDS) in the atmosphere of exoplanet K2-18b, which orbits its star in the habitable zone. The detection has been published in The Astrophysical Journal Letters. 

The KATRIN (Karlsruhe Tritium Neutrino Experiment) team has published the most accurate measurement to date of the upper limit of the neutrino mass in the journal Science, establishing it at 0.45 electronvolts (eV), less than a millionth of the mass of an electron. The KATRIN experiment, launched in 2018 in Germany, will finalise its neutrino mass measurement campaign this year, having reached 1,000 days of data acquisition.

Only 9.5% of plastics produced globally in 2022 were generated from recycled materials. The findings, published in Communications Earth & Environment, are part of a comprehensive analysis of the global plastics sector, which also reveals a large increase in the amount of plastic being disposed of by incineration and substantial regional differences in its consumption.

While some studies have suggested that having a mother with Alzheimer's may increase the risk of developing the disease, a new study reveals that having a father with the disease may be related to a greater spread of tau protein in the brain, which is a sign of the disease. The study, published in Neurology, does not prove that having a father with Alzheimer's causes these brain changes; it only shows an association.

A set of articles published in Nature and Nature Methods draws a high-resolution map of the structure of and connections between the brain cells of mice. The map is based on data from a single cubic millimetre of brain and includes more than 200,000 cells, around 84,000 neurons and 524 million synaptic connections. Although this is a very small part of the mouse brain, it will help us understand how different types of cells work together.

An international team with Spanish participation has analysed the usefulness of a blood biomarker - the p-tau217 protein - for detecting Alzheimer's disease in 1,767 patients. According to the authors, who publish the results in the journal Nature Medicine, the test has detected the disease with high reliability in four hospital cohorts, as well as in a primary care cohort. They add that it is an assay that can be easily implemented in clinical laboratories and is already routinely used in some centres in Spain.

EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.